Compounding: FDA Stepping Up Enforcement With Warning Letters?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA calls North Carolina compounder’s products misbranded and adulterated after the company did not receive valid prescriptions for a number of products it made and agency found several GMP violations.